1. Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
   Burak Can Depboylu et al, 2023, Texas Heart Institute Journal CrossRef
2. Effect of alprostadil plus cilostazol on the treatment outcomes and inflammatory factors in patients with lower extremity arteriosclerosis obliterans receiving evidence-based care
   Hai Liang et al, 2024, Clinical Hemorheology and Microcirculation CrossRef
3. Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research
   Meng-di Li et al, 2020, Current Medicinal Chemistry CrossRef